Clinical trials: DLBCL, Nos Genetic Subtypes
Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.
- Conditions
- Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL
- Trial name
- C402 (NCT06830031)
- Testing
- C402-CD19-CAR
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Exuma Biotechnology Ltd.